Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3.

We have investigated the effects of short-term neoadjuvant and long-term androgen deprivation therapies (ADTs) on β-microseminoprotein (MSMB) and cysteine-rich secretory protein-3 (CRISP3) expression in prostate cancer patients. We also studied if MSMB expression was related to genotype and epigenet...

Full description

Bibliographic Details
Main Authors: Dahlman, A, Edsjö, A, Halldén, C, Persson, J, Fine, S, Lilja, H, Gerald, W, Bjartell, A
Format: Journal article
Language:English
Published: 2010
_version_ 1797089681486118912
author Dahlman, A
Edsjö, A
Halldén, C
Persson, J
Fine, S
Lilja, H
Gerald, W
Bjartell, A
author_facet Dahlman, A
Edsjö, A
Halldén, C
Persson, J
Fine, S
Lilja, H
Gerald, W
Bjartell, A
author_sort Dahlman, A
collection OXFORD
description We have investigated the effects of short-term neoadjuvant and long-term androgen deprivation therapies (ADTs) on β-microseminoprotein (MSMB) and cysteine-rich secretory protein-3 (CRISP3) expression in prostate cancer patients. We also studied if MSMB expression was related to genotype and epigenetic silencing. Using an Affymetrix cDNA microarray analysis, we investigated the expression of MSMB, CRISP3, androgen receptor (AR), KLK3 and Enhancer of Zeste Homologue-2 (EZH2) in tissue from prostate cancer patients receiving (n=17) or not receiving (n=23) ADT before radical prostatectomy. MSMB, CRISP3 and AR were studied in tissue from the same patients undergoing TURP before and during ADT (n=16). MSMB genotyping of these patients was performed by TaqMan PCR. MSMB and KLK3 expression levels decreased during ADT. Expression levels of AR and CRISP3 were not affected by short-term ADT but were high in castration-resistant prostate cancer (CRPC) and metastases. Levels of EZH2 were also high in metastases, where MSMB was low. Genotyping of the MSMB rs10993994 polymorphism showed that the TT genotype conveys poor MSMB expression. MSMB expression is influenced by androgens, but also by genotype and epigenetic silencing. AR and CRISP3 expression are not influenced by short-term ADT, and high levels were found in CRPC and metastases.
first_indexed 2024-03-07T03:07:33Z
format Journal article
id oxford-uuid:b3112bdb-0aaf-48f0-a575-bc7c85187f6d
institution University of Oxford
language English
last_indexed 2024-03-07T03:07:33Z
publishDate 2010
record_format dspace
spelling oxford-uuid:b3112bdb-0aaf-48f0-a575-bc7c85187f6d2022-03-27T04:16:23ZEffect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:b3112bdb-0aaf-48f0-a575-bc7c85187f6dEnglishSymplectic Elements at Oxford2010Dahlman, AEdsjö, AHalldén, CPersson, JFine, SLilja, HGerald, WBjartell, AWe have investigated the effects of short-term neoadjuvant and long-term androgen deprivation therapies (ADTs) on β-microseminoprotein (MSMB) and cysteine-rich secretory protein-3 (CRISP3) expression in prostate cancer patients. We also studied if MSMB expression was related to genotype and epigenetic silencing. Using an Affymetrix cDNA microarray analysis, we investigated the expression of MSMB, CRISP3, androgen receptor (AR), KLK3 and Enhancer of Zeste Homologue-2 (EZH2) in tissue from prostate cancer patients receiving (n=17) or not receiving (n=23) ADT before radical prostatectomy. MSMB, CRISP3 and AR were studied in tissue from the same patients undergoing TURP before and during ADT (n=16). MSMB genotyping of these patients was performed by TaqMan PCR. MSMB and KLK3 expression levels decreased during ADT. Expression levels of AR and CRISP3 were not affected by short-term ADT but were high in castration-resistant prostate cancer (CRPC) and metastases. Levels of EZH2 were also high in metastases, where MSMB was low. Genotyping of the MSMB rs10993994 polymorphism showed that the TT genotype conveys poor MSMB expression. MSMB expression is influenced by androgens, but also by genotype and epigenetic silencing. AR and CRISP3 expression are not influenced by short-term ADT, and high levels were found in CRPC and metastases.
spellingShingle Dahlman, A
Edsjö, A
Halldén, C
Persson, J
Fine, S
Lilja, H
Gerald, W
Bjartell, A
Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3.
title Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3.
title_full Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3.
title_fullStr Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3.
title_full_unstemmed Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3.
title_short Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3.
title_sort effect of androgen deprivation therapy on the expression of prostate cancer biomarkers msmb and msmb binding protein crisp3
work_keys_str_mv AT dahlmana effectofandrogendeprivationtherapyontheexpressionofprostatecancerbiomarkersmsmbandmsmbbindingproteincrisp3
AT edsjoa effectofandrogendeprivationtherapyontheexpressionofprostatecancerbiomarkersmsmbandmsmbbindingproteincrisp3
AT halldenc effectofandrogendeprivationtherapyontheexpressionofprostatecancerbiomarkersmsmbandmsmbbindingproteincrisp3
AT perssonj effectofandrogendeprivationtherapyontheexpressionofprostatecancerbiomarkersmsmbandmsmbbindingproteincrisp3
AT fines effectofandrogendeprivationtherapyontheexpressionofprostatecancerbiomarkersmsmbandmsmbbindingproteincrisp3
AT liljah effectofandrogendeprivationtherapyontheexpressionofprostatecancerbiomarkersmsmbandmsmbbindingproteincrisp3
AT geraldw effectofandrogendeprivationtherapyontheexpressionofprostatecancerbiomarkersmsmbandmsmbbindingproteincrisp3
AT bjartella effectofandrogendeprivationtherapyontheexpressionofprostatecancerbiomarkersmsmbandmsmbbindingproteincrisp3